✦ LIBER ✦

P107 Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications

✍ Scribed by M. Kaminski; L. Rosen; D. Gordon; M. Zheng; Y. Hei

Book ID: 114315830
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 162 KB
Volume: 14
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(05)80143-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P141 Breast cancer patients without pain

P141 Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate

✍ L. Costa; Y.-M. Chen 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Zoledronic acid is superior to pamidrona

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who